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(PCR)-clamping method reported to be effective in detect-
ing post-zygotic mutations in peripheral blood from 
patients with fibrous dysplasia; and to evaluate the fre-
quency of this post-zygotic mutation in PDB patients. We 
used a locked nucleic acid (LNA) specifically designed for 
the SQSTM1/P392L mutation, which blocks the wild-type 
allele amplification during the PCR. DNA from 376 pagetic 
patients and 297 controls, all without any SQSTM1/P392L 
germinal mutation, was analyzed. We found that 4.8 % of 
PDB patients and 1.4 % of controls were carriers of this 
post-zygotic mutation [p = 0.013, OR 3.68 (1.23; 11.00)]. 
PDB patient carriers of a post-zygotic mutation had a lower 
number of affected bones and Renier’s index than patients 
carrying a germinal mutation, suggesting a lower disease 
extension. We also demonstrated that this post-zygotic 
mutation was restricted to the monocytic lineage. These 
results confirmed that LNA PCR clamping is effective for 
the detection of SQSTM1/P392L post-zygotic mutations, 
which may occur in patients with PDB.
Introduction
Paget’s disease of bone (PDB) is the second most frequent 
metabolic bone disorder after osteoporosis, affecting up 
to 3 % of adults over 55 years of age (Collet et al. 2007). 
PDB is characterized by focal increases in bone turnover, 
affecting one or several bones, and resulting in abnormal 
bone architecture and weakened bone strength (Michou 
et al. 2006). Although the exact etiology of the disease is 
still unknown, the genetic component plays an important 
role in its pathophysiology. In fact, one-third of patients 
have a familial form of this disease, which is transmit-
ted in an autosomal dominant mode of inheritance with 
incomplete penetrance (Michou and Brown 2011). Several 
Abstract Paget’s disease of bone (PDB) is transmitted, 
in one-third of cases, in an autosomal dominant mode of 
inheritance with incomplete penetrance. The SQSTM1/
P392L germinal mutation is the most common muta-
tion associated with PDB. Given the focal nature of PDB, 
one team of investigators showed that SQSTM1/P392L 
somatic mutations could occur in pagetic bone lesions in 
the absence of germinal mutations detectable in the periph-
eral blood. The objectives of this study were to develop a 
reliable method to detect SQSTM1/P392L post-zygotic 
mutations, by optimizing a polymerase chain reaction 
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chromosomal regions have been linked to PDB, confirm-
ing its genetic heterogeneity. The 5q35-qter locus was first 
reported in the French-Canadian population, and led to the 
identification of the first germinal mutation associated with 
PDB. This substitution of a cytosine to a thymine at posi-
tion 1,215 in the Sequestosome 1 (SQSTM1) gene results 
in the substitution of the proline at position 392 to a leu-
cine (p.Pro392Leu, called here P392L) in the p62 protein 
(Laurin et al. 2001, 2002). As of now, more than 20 muta-
tions in the SQSTM1 gene have been described (Chung and 
Van Hul 2011; Hocking et al. 2002; Morissette et al. 2006). 
SQSTM1 mutations are reported in similar frequencies 
across countries: SQSTM1 mutations are present in 24.5 % 
of patients with a familial history of PDB and 10.5 % of 
unrelated PDB patients in Australia (Rea et al. 2009). In 
Italy, 36.9 and 9.7 % of patients with or without a familial 
history of PDB, respectively, were carriers of a SQSTM1 
mutation (Gennari et al. 2010), and similar frequencies 
were also observed in United Kingdom and New Zea-
land (Cundy et al. 2011; Hocking et al. 2004). In United 
States, SQSTM1 mutations are present in 20.5 % of patients 
with a familial history of PDB, while none were reported 
in sporadic patients (Rhodes et al. 2008). However, the 
SQSTM1/P392L mutation remains the most frequent muta-
tion linked to PDB, with an overall frequency of 23.6 % 
in familial cases, and 7.1 % in unrelated patients (Moris-
sette et al. 2006). In the French-Canadian population, only 
the SQSTM1/P392L mutation is present, with frequencies 
of 46 % in familial cases, and 16 % in unrelated patients 
(Morissette et al. 2006). Environmental factors also play 
an important role in PDB pathogenesis, in particular viral 
infections, as pagetic osteoclasts frequently express the 
measles virus nucleocapsid protein (MVNP) (Teramachi 
et al. 2014).
PDB has an asymmetrical distribution and remains 
highly localized to affected bones, patients rarely devel-
oping new lesions after diagnosis (Roodman and Windle 
2005). To explain this focal nature, some authors suggested, 
and then showed, that somatic mutations in the SQSTM1 
gene could occur in pagetic bone lesions. Indeed, one team 
has reported a SQSTM1/P392L mutation in affected bone 
of two unrelated patients with PDB, but not in their periph-
eral blood, suggesting a somatic origin for these mutations 
(Merchant et al. 2009). Another independent study failed 
to detect any somatic mutations of the SQSTM1 gene in 
osteoblasts and bone marrow cells culture of PDB-affected 
patients (Matthews et al. 2009). Thus, these results may 
suggest that SQSTM1/P392L somatic mutations can be 
detected in pagetic bone lesions, but not in bone marrow of 
PDB patients.
Fibrous dysplasia (FD) is a focal bone disorder with an 
asymmetrical mono- or polyostotic distribution, like PDB. 
FD is caused by post-zygotic mutations in the Guanine 
Nucleotide-binding Protein Alpha-Stimulating activity 
(GNAS) gene, encoding for the α-subunit of the Gs protein. 
Post-zygotic mutations are somatic mutations occurring 
during the early development of the zygote, resulting in a 
mosaic distribution of normal and mutant cells in tissues or 
organs of affected individuals (Weinstein 2006). Most of 
the time, the mutation reported in FD is a substitution of 
the arginine at position 201 of the Gs protein to a histidine 
or a cysteine, and, rarely, to a glycine or a leucine (Michou 
and Brown 2010). Since the detection of these post-zygotic 
mutations is difficult without practicing a bone biopsy, 
a sensible polymerase chain reaction (PCR)-clamping 
method has been developed. This technique used a peptide 
nucleic acid (PNA), a primer that specifically blocks the 
amplification of the wild-type allele; thereby, improving 
the sensitivity to detect the mutant allele, even if this one 
was present in low copy number in DNA from peripheral 
blood of affected individuals (Lietman et al. 2005).
Given the similarities in the skeletal distribution between 
FD and PDB and the possible presence of SQSTM1/P392L 
somatic mutations in pagetic bone lesions, we hypothesized 
that the optimization of the PCR method, developed to 
detect GNAS post-zygotic mutations in FD, would allow 
us to detect SQSTM1/P392L post-zygotic mutations in the 
peripheral blood of patients with PDB. Thus, the objectives 
of this study were to develop a reliable method to detect 
SQSTM1/P392L post-zygotic mutations and to evaluate the 
frequency of this post-zygotic mutation in PDB.
Materials and methods
Individuals
This study was approved by the CHU de Québec Ethics 
Committee, and all participants, affected or not, signed a 
consent form before entering the study. A complete bone 
evaluation, including total serum alkaline phosphatase 
(sALP) measurement, skull and pelvis X-rays and a whole-
body bone scan was performed for each patient. The cri-
teria used to diagnose PDB were: (1) an increase in total 
sALP level and/or (2) a typical aspect of PDB on the bone 
X-rays and/or (3) an abnormal whole-body bone scan, as 
previously reported (Laurin et al. 2001). Patients with FD 
were diagnosed on a typical bone aspect by the use of 
imaging. All patients with FD studied here were French-
Canadians. The mean age was 43.5 ± 14.6 years, 50.0 % 
of them had only one bone affected, and 60.0 % were male. 
Patients with PDB originated from three different coun-
tries: Canada (French-Canadians from the province of 
Quebec), France and United States (New York city area). 
Either they suffered from a familial form of PDB or they 
were considered as unrelated affected individuals. All 
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participants studied were screened for germinal mutations 
in exons 7 and 8 of the SQSTM1 gene, and none of them 
were carrier of a SQSTM1 gene mutation. In the French-
Canadian patients, the mean age at the time of the study 
was 80.3 ± 10.9 years, 57.9 % were male and 45.2 % had 
a monostotic disease (Laurin et al. 2002; Morissette et al. 
2006). In the French population, the mean age of PDB 
patients was 70.7 ± 14.0 years, 56.3 % were male and 
31.3 % had a monostotic disease. Finally, in the New York 
city area population, 44.4 % were male and 60.3 % had a 
monostotic bone involvement (the mean age was not avail-
able for this population) (Michou et al. 2010, 2011). Clini-
cal characteristics of pagetic patients, including total sALP 
(expressed as the number of times the midpoint of normal 
range to normalize results between patients), the age at 
PDB diagnosis, the number of bone sites affected by PDB 
and the skeletal extension calculated by the Rénier’s index, 
were collected (Renier et al. 1995). Controls were healthy 
individuals from the French-Canadian population without 
any personal or familial history of PDB based on a ques-
tionnaire, and with normal total sALP levels at inclusion. 
For three of them, a bone scan was performed (see results 
section). The mean age of these healthy individuals at the 
time of the study was 76.7 ± 10.9 years, and 28.4 % were 
male. For each participant, DNA from peripheral blood 
mononuclear cells (PBMCs) was extracted according to 
standard procedures.
Development of the PCR-clamping method  
for the GNAS/R201L mutation in FD patients
Despite good results have been obtained in detecting 
somatic mutations in FD using a PNA in the literature 
(Lietman et al. 2005), the LNA has many advantages: the 
LNA has a higher stability when bonded to DNA, a higher 
affinity for complementary DNA sequences than PNA or 
than DNA itself, and a better sensitivity to the presence of 
mismatched bases (Braasch and Corey 2001). For all these 
reasons, we preferred, in our study, optimizing the PCR-
clamping method by the use of an LNA instead of a PNA. 
We optimized this PCR-clamping technique in 10 patients 
with FD, in accordance with the literature (Lietman et al. 
2005). The LNA was specifically designed for the GNAS/
R201L mutation and synthesized by Exiqon (Woburn, 
MA, USA) (5′-TTCGCTGCCGTGTCCTGAC-3′). A por-
tion of exon 8 of the GNAS gene was amplified by PCR 
using the following primers: forward 5′-CACCCCACGTG 
TCTTTCTTT-3′ and reverse 5′-CACAGCATCCTACC 
GTTGAA-3′. Each 20 µL PCR contained 40 ng of DNA, 
1× PCR buffer, 1.5 mM MgCl2, 0.4 µM of each primer, 
0.2 mM of dNTPs, 1 M of betaine, 0.4 U of JumpStart 
Taq DNA Polymerase and 5 µM of the specific LNA. 
PCR conditions were an initial denaturation at 95 °C for 
5 min, followed by 38 cycles at 95 °C for 30 s (denatura-
tion step), 74 °C for 30 s (LNA hybridization step), 55 °C 
for 30 s (primer annealing step) and 72 °C for 30 s (exten-
sion step), and an additional extension step was performed 
at 72 °C for 8 min. Amplification products were purified 
and sequenced with Big Dye Deoxy Terminator v 3.1 Cycle 
(Applied Biosystems) on an ABI 3730xl sequencer at the 
Plateforme de séquençage et de génotypage des génomes 
du Centre de recherche du CHU de Québec. The DNA 
sequences obtained were analyzed with Staden package 
version 1.6 (Staden 1996). All chromatograms were inde-
pendently analyzed by two readers (SGB, LM). In case of 
discordant interpretation, the PCR clamping followed by 
the sequencing analysis was repeated. All sequences show-
ing a post-zygotic mutation were done at least twice to con-
firm the results.
Optimization of the PCR-clamping method  
for the SQSTM1/P392L mutation in PDB patients
In this study, we only investigated the SQSTM1/P392L 
mutation, the most common mutation associated with PDB 
so far, since this mutation occurs at a hypermutable CpG 
dinucleotide sequence, a mutational hotspot (Laurin et al. 
2002; Morissette et al. 2006). We used an LNA specifically 
designed for this SQSTM1/P392L mutation, which was 
synthesized by Exiqon (Woburn, MA, USA) (5′-CAGCC 
GCGGGTCAGC-3′). To confirm the LNA’s ability to 
block the wild-type allele amplification, we analyzed DNA 
from three types of control individuals: one healthy indi-
vidual non-carrier of a SQSTM1/P392L germinal muta-
tion, one pagetic patient heterozygous for the SQSTM1/
P392L germinal mutation, and one patient homozygous 
for this germinal mutation. A portion of exon 8 of the 
SQSTM1 gene was amplified using the following prim-
ers: forward 5′-TGGCTAACTGGCCTGTTCTT-3′ and 
reverse 5′-AATGGCTTCTTGCACCCTAA-3′. PCR mix 
and conditions were the same as those used for the detec-
tion of the GNAS/R201L post-zygotic mutation. Given 
the small amount of amplified fragments in the presence 
of LNA, we performed a nested PCR using the following 
primers: forward 5′-TACAGGGAAAGCAGGTCCAC-3′ 
and reverse 5′-TCCTGGAAGAAGGCAGAGAA-3′, and 
standard PCR conditions. Amplification products were 
purified, sequenced, and analyzed as previously men-
tioned. Once the LNA PCR-clamping technique was accu-
rate, we analyzed DNA from 297 French-Canadian PDB 
patients, of whom 75 had a familial form of the disease, 
16 PDB patients from the French population, of whom five 
suffered from a familial form of the disease, 63 unrelated 
PDB patients from the New York city area population, and 
297 French-Canadian healthy controls, all non-carrier of a 
SQSTM1/P392L germinal mutation. Finally, to ensure that 
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the post-zygotic mutations detected were not false positives 
due to the PCR method’s limits, we analyzed DNA from 19 
individuals diagnosed with a rare bone disease and who are 
not likely to carry a SQSTM1/P392L post-zygotic mutation.
Distribution of the SQSTM1/P392L post-zygotic mutation 
in blood and saliva tissues of PDB patients
Blood samples (50 mL) were collected from three PDB 
patient carriers of a SQSTM1/P392L post-zygotic mutation, 
one PDB patient heterozygous for the SQSTM1/P392L 
germinal mutation and one PDB patient non-carrier of 
any mutation within the SQSTM1 gene. PBMCs were iso-
lated by Ficoll density gradient and dextran sedimentation. 
The isolated PBMCs were then centrifuged and incubated 
20 min in PBS/0.2 % BSA with the following antibodies: 
PercpCy5.5-conjugated anti-human CD45, PE-conjugated 
anti-human CD14, FITC-conjugated anti-human CD3, 
APC-conjugated anti-human CD19 and V450-conjugated 
anti-human CD56, according to the manufacturer’s pro-
tocol. Monocytes and lymphocytes were further sorted 
using the BD SORP FACSAria II cytometer at the Plate-
forme d’imagerie et cytométrie du Centre de recherche 
du CHU de Québec. Cells considered as monocytes were 
CD45+CD14+ cells, and those considered as lymphocytes 
were CD45+CD3+ (T lymphocytes), CD45+CD19+ (B 
lymphocytes) and CD45+CD56+ (natural killers) cells. 
Saliva samples (2 mL) were collected from two PDB 
patient carriers of a SQSTM1/P392L post-zygotic mutation 
using the Oragene-DNA kit, provided by DNA Genotek 
(Ottawa, ON, Canada). DNA was extracted from mono-
cytes, lymphocytes, and saliva separately using standard 
procedures, and the LNA PCR-clamping method was per-
formed as previously described to detect SQSTM1/P392L 
post-zygotic mutations in these cell populations.
Distribution of the SQSTM1/P392L post-zygotic mutation 
in bone tissue of a PDB patient
A transiliac bone biopsy was performed on the only patient 
carrier of a SQSTM1/P392L post-zygotic mutation who had 
a pelvic site involved with PDB, using a Rochester trephine 
(inner diameter 7–8 mm). Bone biopsy was bi-sectioned 
with low ISOMET speed saw (Buehler, Canada) and one 
section was frozen at −80 °C for laser microdissection of 
osteoclasts, before DNA extraction and sequencing. The 
other part of the biopsy was fixed in Phosphate buffered 
10 % formaldehyde prior to being decalcified in 14 % 
EDTA for 3 days. Then, this bone sample was embedded in 
paraffin. A 5-μm-thick section was sectioned with a Leica 
RM2245 microtome and H&E stained to confirm that the 
bone biopsy was indeed in a pagetic area.
Estimation of the copy number of the SQSTM1/P392L 
post-zygotic mutation
A fluorescent-based Realtime PCR quantification was per-
formed on 10 ng of genomic DNA from 18 PDB patients 
carrier of a SQSTM1/P392L post-zygotic mutation, two 
PDB patient carriers of a homozygous SQSTM1/P392L 
germinal mutation, two PDB patients heterozygous for this 
same mutation, and 15 individuals non-carrier of any muta-
tion. We used the LightCycler 480 (Roche Diagnostics, 
Mannheim, DE), and reagent LightCycler 480 SYBRGreen 
I Master (Roche Diagnostics, Indianapolis, IN, USA) as 
described by the manufacturer, with 2 % DMSO. A por-
tion of exon eight of the SQSTM1 gene was amplified using 
two specific forward LNA-enhanced qPCR primers syn-
thetized by Exiqon (Woburn, MA, USA): 5′-TGTTTCGG 
CAGAGGCTGACC + C-3′ for the wild-type allele, and 
5′-TGTTTCGGCAGAGGCTGACC + T-3′ for the mutant 
allele. The reverse primer was the same for both reactions 
and was synthesized without LNA (5′-TCCGATGTCATA 
GTTCTTGGTCTGC-3′). PCR conditions were 40 cycles 
at 90 °C for 10 s (denaturation), 65 °C for 10 s (annealing), 
72 °C for 14 s (elongation) and 80 °C for 5 s (reading). A 
melting curve was performed to assess non-specific signal, 
and a standard curve was established using known amount 
of purified PCR products. Calculation of the number of 
copies of each mRNA was performed using second deriva-
tive method and a standard curve of Cp versus logarithm 
of the quantity, using the LightCycler 480 v1.5 program 
provided by the manufacturer (Roche Diagnostics, Man-
nheim, DE). Finally, the percentage of the mutant allele 
T versus wild-type allele C was calculated for each sam-
ple. All manipulations and analyses were performed at the 
Plateforme d’expression génique du Centre de recherche du 
CHU de Québec.
Statistical analyses
Frequencies of the SQSTM1/P392L post-zygotic mutation 
between cases and controls were compared using a Chi-
square test, with odds ratio (OR) and 95 % confidence 
interval (95 %CI) calculations. For the phenotype–geno-
type associations, we compared PDB patients with post-
zygotic mutations to patients with germinal mutations and 
without any mutation within the SQSTM1 gene, for the 
following items: total sALP levels, age at diagnosis, num-
ber of affected bones, and Renier’s index. Analyses relied 
on Student t test for continuous variables, and Chi-square 
or Fisher exact tests when appropriate for nominal val-
ues. All analyses were performed using IBM SPSS Statis-
tics 21 and a p value of <0.05 was considered statistically 
significant.
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Results
Development of the PCR-clamping method  
for the GNAS/R201L mutation in FD patients
The LNA PCR-clamping method was developed with 
DNA from PBMCs of ten patients with FD and two 
healthy controls. Figure 1 shows that the LNA specifically 
designed for the GNAS/R201L mutation was effective to 
block the wild-type allele amplification. Direct sequencing 
of the PCR products in presence of the LNA showed that 
one individual was carrier of a GNAS/R201L post-zygotic 
mutation, which was not detected in the absence of the 
LNA (Fig. 2). The FD patient carrier of the GNAS/R201L 
post-zygotic mutation, who was the only one to have a 
McCune-Albright syndrome, also seemed to have a more 
extensive disease than non-mutated FD patients (see FD-
02, Table 1). In fact, he had 11 FD-affected bones, while 
the mean number in this cohort was 3.2 ± 3.4 affected 
bones. These results suggested that the GNAS/R201L 
Fig. 1  LNA PCR-clamping method for the GNAS/R201L muta-
tion in patients with fibrous dysplasia (FD). PCR was performed in 
the absence (−) or in the presence (+) of the LNA. DNA from FD 
patients (lanes labeled 1–4) and healthy controls (lanes labeled C) 
was used. A band of 460 bp was present when PCR was performed 
in absence of the LNA, and the intensity was reduced by the addition 
of the LNA in the PCR mix, as expected. PCR fragments were loaded 
on a 1 % agarose gel. The water lane represented a control without 
DNA, and the absence of a PCR band indicated that there was no 
contamination in this experience
Fig. 2  Sequencing analysis with and without the use of the LNA 
PCR-clamping method in patients with fibrous dysplasia (FD). For-
ward and reverse short nucleotide sequence analysis of the region 
covering the GNAS/R201L mutation is presented. Left panel shows 
the sequences in absence of the LNA, and right panel shows the DNA 
sequence in presence of the LNA. a DNA sequence of a FD patient 
non-carrier of a GNAS/R201L post-zygotic mutation. Regardless of 
the presence of the LNA, only the wild-type G allele was amplified. b 
DNA sequence of the patient FD-02, who is carrier of a GNAS/R201L 
post-zygotic mutation. In absence of the LNA, only the wild-type G 
allele was amplified, while in presence of the LNA, both wild-type G 
and mutant A allele were amplified
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post-zygotic mutation can be detected with this PCR-
clamping technique in FD.
Optimization of the PCR-clamping method  
for the SQSTM1/P392L mutation in PDB patients
The PCR performed on DNA from PBMCs of three control 
individuals confirmed that the LNA specifically designed for 
the SQSTM1/P392L mutation was very effective to block the 
wild-type allele amplification (Fig. 3). Then, the PCR-clamp-
ing method was performed on DNA from PBMCs of a subset 
of patient non-carriers of a germinal mutation to search for 
SQSTM1/P392L post-zygotic mutations. Direct sequencing 
of PCR products showed that one patient in this subset was 
carrier of a SQSTM1/P392L post-zygotic mutation (Fig. 4). 
These results suggested that this LNA PCR-clamping method 
was effective to detect SQSTM1/P392L post-zygotic muta-
tions in peripheral blood of pagetic patients.
Prevalence of the SQSTM1/P392L post-zygotic mutation 
in PDB patients
After verifying the accuracy and precision of the PCR-
clamping method, we evaluated the prevalence of the 
Table 1  Description of the main clinical characteristics of patients (n = 10) with fibrous dysplasia (FD)
a
 FD-02 was found to be carrier of a GNAS/R201L post-zygotic mutation in our study
Patient ID Sex Age at  
diagnosis (years)
Affected bones Extraosseous involvements or  
complications of FD
FD-01 M 40 Sphenoid None
FD-02a M 15 Skull, right maxillary, mandible, rib cage,  
both humeri, right radius, left ulna, right  
pelvis, right femur, right tibia
McCune Albright syndrome, back and neck café 
au lait skin lesions, hypophosphatemia, erectile 
dysfunction
FD-03 M 26 Right temporal region Stenosis of the right external auditory canal
FD-04 M 24 Left mastoid and occipital regions, sphenoid,  
left mandible
Bacterial meningitis, complete deafness on the 
left side, infertility
FD-05 M 45 Both tibias Mazabraud’s syndrome (left calf and right thigh 
myxoma in addition to FD)
FD-06 F 28 Left mastoid and occipital regions None
FD-07 F 43 Skull, D9 and L2 vertebrae, left ischion, left  
sacroiliac region, both femurs
None
FD-08 M 24 Sphenoid None
FD-09 F 57 Right frontal region, ethmoid, nasal bone,  
malar region, right mandible
None
FD-10 F 26 Skull None
Fig. 3  Optimization of the LNA PCR-clamping method for the 
SQSTM1/P392L mutation in patients with Paget’s disease of bone 
(PDB). PCR was performed in absence (−) or in the presence (+) 
of the LNA. DNA from PBMCs of a non-mutated healthy individ-
ual (lane labeled 1), a patient with a heterozygous genotype for the 
SQSTM1/P392L germinal mutation (lane labeled 2), and a patient 
with a homozygous genotype for the SQSTM1/P392L germinal muta-
tion (lane labeled 3) was used. A band of 600 bp was present when 
PCR was performed in absence of the LNA. For the mutated individ-
uals, this band was still present when the LNA was added in the PCR 
mix, while completely absent for the non-mutated healthy individual. 
PCR fragments were loaded on a 1 % agarose gel. The water lane 
represented a control without DNA, and the absence of a PCR band 
indicated that there was no contamination in this experience
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SQSTM1/P392L post-zygotic mutation in 376 PDB-
affected patients from three distinct populations (Que-
bec, France and New York city area) and 297 French-
Canadian healthy individuals, all non-carriers of a 
SQSTM1/P392L germinal mutation. In the French-
Canadian population, we detected a SQSTM1/P392L 
post-zygotic mutation in 17 (5.7 %) patients with PDB 
(Table 2). Among them, five unrelated patients had a 
familial autosomal dominant form of the disease, but 
with absence of germinal or post-zygotic SQSTM1/
P392L mutation in their relatives. In the French popu-
lation, one (6.3 %) patient with an autosomal dominant 
familial form of PDB was also carrier of a SQSTM1/
P392L post-zygotic mutation (Table 2). We did not 
detect this post-zygotic mutation in patients with PDB 
from the New York city area population. Also, this post-
zygotic mutation was not present in non-pagetic patients 
with a rare bone disease, further supporting that the 
post-zygotic mutations observed in PDB patients were 
not false positives due to the limits of the PCR method. 
Overall, in the three cohorts, we found 18 (4.8 %) PDB 
patients carriers of a SQSTM1/P392L post-zygotic muta-
tion, the difference with healthy controls being statisti-
cally significant [p = 0.013, OR 3.68 (1.23; 11.00)]. Sur-
prisingly, we found four (1.4 %) carriers of a SQSTM1/
P392L post-zygotic mutation in a priori healthy French-
Canadian individuals, based on questionnaire and total 
sALP measurements at inclusion. We were able to per-
form clinical examinations and whole-body bone scan in 
three of these healthy individuals to search if they had 
Fig. 4  Sequencing analysis 
with and without the utiliza-
tion of the LNA PCR-clamping 
method in patients with Paget’s 
disease of bone (PDB). Forward 
and reverse short nucleotide 
sequence analysis of the region 
covering the SQSTM1/P392L 
mutation is presented. Left 
panel shows the sequences in 
absence of the LNA, and right 
panel shows the DNA sequence 
in presence of the LNA. a DNA 
sequence of a PDB patient car-
rier of a SQSTM1/P392L post-
zygotic mutation. In absence of 
the LNA, only the wild-type C 
allele was amplified, while in 
presence of the LNA, both wild-
type C and mutant T allele were 
amplified. b DNA sequence of a 
non-mutated healthy individual. 
Regardless of the presence of 
the LNA, only the wild-type 
C allele was amplified. c DNA 
sequence of a PDB patient car-
rier of a heterozygous SQSTM1/
P392L germinal mutation. 
In absence of the LNA, both 
wild-type C and mutant T 
allele were amplified; while in 
presence of the LNA, only the 
mutant T allele was amplified. 
d DNA sequence of a PDB 
patient carrier of a homozy-
gous SQSTM1/P392L germinal 
mutation. Regardless of the 
presence of the LNA, only the 
mutant T allele was amplified, 
as expected
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asymptomatic PDB. The clinical exam of the first one, an 
81-year-old woman, demonstrated a frank hypertrophy 
of the internal extremity of the right clavicle, consistent 
with a diagnosis of PDB, but the bone scan only demon-
strated degenerative lumbar and knee fixations, and no 
X-rays were available. The second healthy control was a 
70-year-old man, without any clinical evidence of PDB. 
His bone scan did not show any fixation suggestive of 
PDB. The third control carrier of a post-zygotic muta-
tion was a 54-year-old woman who reported permanent 
pain of the right parietal bone, but her bone scan and 
skull X-rays did not show any evidence of PDB.
Phenotype–genotype associations
PDB patients carrier of a SQSTM1/P392L post-zygotic 
mutation had a statistically significant lower number of 
affected bones than patients carrying a germinal muta-
tion (2.2 ± 1.4 vs. 5.2 ± 4.3 affected bones, respec-
tively, p = 0.002). These patient carriers of a post-zygotic 
mutation also had a lower Renier’s index than patients 
carrying a germinal mutation (8.2 ± 5.7 vs. 15.7 ± 13.4, 
p = 0.043), suggesting a lower disease extent (Table 3). 
Within the group of PDB patient carriers of a post-zygotic 
mutation, those with a familial form of the disease had 
3.0 ± 2.35 affected bones, compared to 1.92 ± 0.86 for 
unrelated PDB patients, suggesting that familial cases had 
a more extensive disease. However, these results are only 
descriptive considering the small sample size. Although 
not statistically significant, PDB patients with post-zygotic 
mutations tended to have a lower age at diagnosis than 
patients without any mutations, and a higher age than 
patients carrying a germinal mutation. Moreover, patient 
carriers of a post-zygotic mutation tended to have a higher 
total sALP level than non-mutated patients, but lower than 
patients with a germinal mutation. These results suggested 
that patients with a SQSTM1/P392L post-zygotic muta-
tion have an intermediate clinical phenotype, between 
patient carriers of a SQSTM1/P392L germinal mutation and 
patients with PDB non-carrier of any SQSTM1 mutation.
Table 2  Description of the main clinical characteristics of pagetic patients (n = 18) carriers of a SQSTM1/P392L post-zygotic mutation
The normal range was 30–120 U/L
sALP serum phosphatase alkaline, × ULN number of times of the upper limit of normal range
a
 For total sALP levels, values are × ULN ± SD
Patient ID Population Family 
history






Affected bones Renier’s 
index (%)
PDB-01 French-Canadian No M 53 1.95 3 Right femur, right clavicle, right 
frontal region
4.82
PDB-02 French-Canadian No F 68 11.99 2 Skull, sacrum 13.00
PDB-03 French-Canadian No M 65 7.73 3 Left pelvis, left femur, lumbar 
vertebra
8.35
PDB-04 French-Canadian No F 30 1.48 1 Left tibia 5.00
PDB-05 French-Canadian No M 42 11.07 1 Sacrum 2.00
PDB-06 French-Canadian No M 49 2.32 2 Right femur, right scapula 7.80
PDB-07 French-Canadian No F 57 2.19 1 Right femur 9.00
PDB-08 French-Canadian No F 63 2.59 3 Skull, right pelvis, right femur 20.00
PDB-09 French-Canadian No M 64 1.28 2 Sacrum, lumbar vertebra 2.65
PDB-10 French-Canadian No M 79 1.55 1 Right humerus 1.17
PDB-11 French-Canadian Yes M 75 1.68 2 Right pelvis, left femur 7.70
PDB-12 French-Canadian No M 66 0.98 3 Right femur, both radius 4.70
PDB-13 French-Canadian No F 64 1.39 1 Left femur 6.00
PDB-14 French-Canadian Yes F 66 0.84 1 Both occipital and parietal regions 3.67
PDB-15 French-Canadian Yes F 67 1.73 5 Left pelvis, sacrum, right femur, 
left fibula, right humerus
17.00
PDB-16 French-Canadian Yes M 58 3.19 6 Left pelvis, sacrum, L1 vertebra, 
left scapula, right tibia, skull
19.22
PDB-17 French-Canadian Yes F 78 1.79 1 Skull 11.00
PDB-18 French Yes M 58 1.22 2 Right pelvis, D7 vertebra 4.8
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Somatic mosaicism of the SQSTM1/P392L post-zygotic 
mutation in PDB patients
Direct sequencing of PCR products from PDB patient carri-
ers of a SQSTM1/P392L post-zygotic mutation showed that 
this mutation was present in the monocytes population, but 
absent in lymphocytes and saliva (Fig. 5). Similar results 
have been observed for the three patients, carrier of a post-
zygotic mutation. The LNA PCR-clamping method per-
formed on DNA from monocytes, lymphocytes and saliva 
suggested that the post-zygotic mutation was restricted to 
the monocytic lineage.
Among the 18 PDB patient carriers of the SQSTM1/
P392L post-zygotic mutation, only one patient with a 
pagetic involvement of the pelvis was eligible for a transi-
liac bone biopsy. This patient was treated with an infusion 
of zoledronic acid 5 mg in 2008. He had normal levels of 
sALP and creatinine at the time of the biopsy. The X-ray 
of his pelvis demonstrated a typical pagetic aspect of the 
right pelvis with prominence of bone sclerosis, cortico-
trabecular dedifferentiation and bone hypertrophy (Sup-
plementary Fig. 1). Unfortunately, the one effort to secure 
active pagetic bone for laser micro-dissection proved inef-
fective, as the biopsy yielded tissue with insignificant cel-
lular activity. Indeed, the osteoclastic activity appeared 
largely decreased in number, and slight fibrosis process 
has been observed in some Howship’s lacunae. An absence 
of osteoblast cells was also observed. Increased cortical 
thicknesses, architectural disorganization with heavily tra-
beculated bone were observed, suggesting a final ‘burn out’ 
phase of pagetic bone, although we cannot definitely rule 
out that this absence of bone cells may result from a techni-
cal problem during the fixation of the bone sample.
Estimation of the copy number of the SQSTM1/P392L 
post-zygotic mutation
For PDB-affected patient carriers of a SQSTM1/P392L 
post-zygotic mutation, the percentage of the mutant T allele 
versus the wild-type C allele was ≤10 % for each DNA 
sample tested. For the PDB patients carrier of a heterozy-
gous SQSTM1/P392L germinal mutation, this percentage 
was >97 %, suggesting that the mutant T allele and the 
wild-type C allele were present in a similar copy num-
ber, as expected. For non-mutated individuals and patients 
homozygous for the germinal SQSTM1/P392L mutation, 
we found about 3 % of contamination.
Discussion
In this study, we developed an LNA PCR-clamping 
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mutation in peripheral blood of one patient with McCune 
Albright syndrome, but none of FD patients, which rep-
resents a mutation rate similar to the one reported in the 
literature (Lietman et al. 2005). We then optimized this 
PCR technique to detect SQSTM1/P92L post-zygotic 
mutations in peripheral blood of patients with PDB. We 
found that 4.8 % of PDB patients and 1.4 % of healthy 
controls were carrier of this post-zygotic mutation. 
Among the PDB patient carriers of a post-zygotic muta-
tion, five of them had an autosomal dominant form of the 
disease, but none of the relatives were carrier of a germi-
nal or post-zygotic SQSTM1 mutation. Since the disease-
causing gene is still unknown in these families, we can-
not rule out that these post-zygotic mutations can act as a 
modifier. Genotype–phenotype associations showed that 
PDB patient carriers of a SQSTM1/P392L post-zygotic 
mutation had a lower number of affected bones and a 
lower Renier’s index than patients carrying a germinal 
mutation, suggesting a less important disease extension. 
We did not find any statistically significant difference in 
the sALP levels between the different mutations groups, 
which is not surprising since most of patients have 
already been treated for PDB. Thereafter, we observed 
that the somatic mosaicism of SQSTM1/P392L muta-
tion was restricted to the monocytic lineage. Indeed, the 
post-zygotic mutation was present in DNA from periph-
eral blood monocytes, but absent from DNA of lympho-
cytes and saliva. Our results, in addition to the presence 
of SQSTM1/P392L somatic mutations reported in pagetic 
bones (Merchant et al. 2009), confirm that SQSTM1/
P392L post-zygotic mutations may occur in patients 
with PDB. The detection of SQSTM1/P392L post-zygotic 
mutations in four healthy individuals, although unex-
pected, may suggest that this post-zygotic mutation has 
Fig. 5  Sequencing analysis with and without the use of LNA PCR-
clamping method in DNA from monocytes, lymphocytes and saliva 
in patients with Paget’s disease of bone (PDB). Forward short nucleo-
tide sequence analysis of the region covering the SQSTM1/P392L 
mutation is presented. Left panel shows the sequences in absence of 
the LNA, and right panel shows the DNA sequences in presence of 
the LNA. Only one example is shown, but similar results have been 
observed for the three PDB patients carrier of a post-zygotic muta-
tion. a DNA sequences of the monocytes population. (1) For the 
PDB patient carrier of a SQSTM1/P392L post-zygotic mutation, only 
the wild-type C allele was amplified in absence of the LNA, while 
in presence of the LNA, both wild-type C and mutant T allele were 
amplified. (2) For the PDB patient carrier of a SQSTM1/P392L ger-
minal mutation, both wild-type C and mutant T alleles were ampli-
fied in absence of the LNA, while only the mutant T allele was 
amplified after the addition of the LNA in the PCR mix. (3) For the 
non-mutated PDB patient, only the wild-type C allele was amplified, 
regardless of the presence of the LNA. b DNA sequences of the lym-
phocytes population from a PDB patient carrier of a SQSTM1/P392L 
post-zygotic mutation. Only the wild-type allele C was amplified, 
regardless of the presence of the LNA. c DNA sequence of the saliva 
cells population from a PDB patient carrier of a SQSTM1/P392L 
post-zygotic mutation. Only the wild-type C allele was amplified, 
regardless of the presence of the LNA
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an incomplete penetrance. Indeed, incomplete penetrance 
has also been reported for the SQSTM1/P392L germinal 
mutation, this penetrance being about 80 % by the sev-
enth decade (Ralston and Albagha 2011). Healthy indi-
vidual carriers of the SQSTM1/P392L germinal mutation, 
even after the age of 55 years and without any clinical 
symptoms of PDB, have also been reported in the litera-
ture (Bolland et al. 2007).
Although we were unable to confirm the presence of 
the SQSTM1/P392L post-zygotic mutation in an affected 
bone, we observed that the presence of this mutation was 
restricted to monocytes, the osteoclasts precursors. Since 
osteoclasts are the primary cells affected by PDB, we 
may hypothesize that a subset of cells originating from 
the monocytic lineage and carrying this mutation could 
contribute focally to the development of PDB. However, 
we cannot rule out the possibility that osteoclasts or their 
precursors may have recirculated from an affected bone in 
the peripheral blood. It will be interesting to determine if 
these monocytes are expressing MVNP to investigate the 
relation between post-zygotic mutations and viral infec-
tion, as it was done for the SQSTM1 germinal mutation 
(Kurihara et al. 2011). In the future, the generation of ani-
mal model carriers of this SQSTM1/P392L post-zygotic 
mutation would be of paramount importance to better 
assess the functional role of post-zygotic mutations in PDB 
pathogenesis.
Our study has some limitations. First, we used an LNA 
blocking the mutation site in the forward sense only. We 
also decided to focus our study only on the SQSTM1/P392L 
mutation since it is the most frequent mutation associated 
with PDB and the only one present in the French-Canadian 
population, and it is located on a mutational hotspot. More 
than 20 mutations in the SQSTM1 gene have been associ-
ated with PDB, and it is likely that they can occur as well in 
a post-zygotic form. Then, the LNA PCR-clamping method 
should be adapted to other SQSTM1 mutations reported in 
PDB to have a better idea of the prevalence of post-zygotic 
mutations in PDB. Alternatively, to facilitate the detection 
of post-zygotic mutations, other sensitive and more high-
throughput genotyping methods, such as single-nucleotide 
polymorphisms arrays and/or next-generation sequencing, 
should be considered (Omoyinmi et al. 2014). On the other 
hand, this study has several strengths. First, the recruitment 
of this large cohort of patients with the systematic collec-
tion of clinical data is a valuable tool to study the genetic 
factors of PDB. Second, we developed and validated a 
successful PCR-clamping method, which ensures its accu-
racy and reproducibility in the detection of low-frequency 
mutations.
In the literature, post-zygotic mutations are defined as 
mutations that arise in development during organogen-
esis, at the zygote stage. These mutations are classically 
unilateral, as evidenced by the topographically limited and 
tissue or organ-restricted clinical manifestations. They usu-
ally cause the development of sporadic disease in individu-
als with unaffected parents (Biesecker and Spinner 2013). 
In this study, our data do not allow us to determine at which 
time the mutation arose during organogenesis, but its pres-
ence in a blood lineage may suggest an early occurrence 
in the development of the zygote. It is important to note 
that there are different classes of mosaic disorders. FD is 
a disorder that manifests only as a mosaicism, since there 
is no familial form of the disease. In fact, this disease is 
caused by mutations that are lethal in the embryonic devel-
opment, which means that they cannot be transmitted 
through the germ line. Cells bearing the mutation can only 
survive when they are in close proximity to wild-type cells 
(Happle 1986). Some disorders, usually transmitted in an 
autosomal dominant pattern of inheritance, have also been 
reported in mosaic forms. Patients with such mosaicism 
can have affected children since the post-zygotic mutation, 
if present in the germ line, would be transmitted to the off-
spring. For example, in neurofibromatosis type 1, even if 
most of the affected individuals are carriers of a germinal 
mutation in the NF1 gene and develop a complete disease 
phenotype, some individuals were reported to have clini-
cal manifestations limited to a tissue or an organ due to 
the presence of post-zygotic mutations in the NF1 gene 
(Biesecker and Spinner 2013; Kaplan et al. 2010). Somatic 
mosaicism due to post-zygotic mutations can result in a 
milder, borderline clinical phenotype which may vary with 
the proportion, usually low, of cells carrying the mutation 
(Forsberg et al. 2013). Thus, our results suggest that, like 
in neurofibromatosis type 1, pagetic patient carriers of a 
SQSTM1/P392L post-zygotic mutation would develop a 
less extensive bone involvement than patients harboring 
the germ line mutation. Indeed, it is possible that the PDB 
extent could be somewhat correlated to the proportion of 
cells carrying the SQSTM1/P392L post-zygotic mutation. 
However, we did not find any particular trend in the lateral-
ity of affected bones in patients carrying the post-zygotic 
mutation, since both sides were affected in most of them. 
In this study, all patients carrying the SQSTM1/P392L 
post-zygotic mutation had a percentage of mutant T allele 
≤10 %. These results could explain why we were not able 
to detect this post-zygotic mutation without the addition of 
the LNA in the PCR mix, and suggest that our technique 
increases the sensibility to detect SQSTM1/P392L muta-
tions in our populations. In fact, the diagnostic perfor-
mance of the PNA to detect GNAS post-zygotic mutations 
in fibrous dysplasia is about 1 %, and about 0.03 % for the 
next-generation sequencing technique (Narumi et al. 2013). 
Our results are in accordance with a possible mutational 
spectrum at germinal, post-zygotic and somatic levels for 
the SQSTM1/P392L mutation. This mutational spectrum, 
64 Hum Genet (2015) 134:53–65
1 3
including post-zygotic mutations, could explain the focal 
nature with the asymmetric bone distribution observed in 
PDB, and contribute to the variable expressivity observed 
in familial forms of PDB with autosomal dominant pattern 
of inheritance.
In conclusion, we developed a reliable LNA PCR-
clamping method to detect SQSTM1/P392L post-zygotic 
mutations in peripheral blood of patients with PDB. Fur-
ther studies in other populations are warranted to deter-
mine more accurately the frequency of the SQSTM1/P392L 
mutations at a germinal, post-zygotic and somatic level, 
respectively, and to determine how post-zygotic mutations, 
within the SQSTM1/P392L mutational spectrum, may con-
tribute to the focal nature of pagetic bone involvement.
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